Company Vinings Holdings Inc. Other OTC

NDYN

US92744A1051

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.

Managers	Title	Age	Since
David Mehalick CEO	Chief Executive Officer	56	28/22/28
Brian Cogley DFI	Director of Finance/CFO	38	17/23/17
Daniel Yerace COO	Chief Operating Officer	41	28/22/28
Colleen Delaney CTO	Chief Tech/Sci/R&D Officer	57	30/23/30
Christine Sheehy CMP	Compliance Officer	57	28/22/28

Members of the board	Title	Age	Since
Philippe Deschamps BRD	Director/Board Member	62	28/22/28
Christopher Cochran BRD	Director/Board Member	55	28/22/28
Christine Sheehy CMP	Compliance Officer	57	28/22/28
Gene Salkind BRD	Director/Board Member	71	28/22/28
Chris Calise BRD	Director/Board Member	51	28/22/28
David Mehalick CEO	Chief Executive Officer	56	28/22/28
Daniel Yerace COO	Chief Operating Officer	41	28/22/28
Tara Maria DeSilva BRD	Director/Board Member	56	28/22/28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,118,593	25,373,891 ( 68.36 %)	0	68.36 %

Name	Equities	%	Valuation
Armistice Capital LLC 8.396 %	3,030,269	8.396 %	975 747 $
David Mehalick 7.208 %	2,601,311	7.208 %	837 622 $
Biofin Ventures LLC 6.650 %	2,400,000	6.650 %	772 800 $
Bull Horn Holdings Sponsor LLC 5.227 %	1,886,582	5.227 %	607 479 $
Christine Sheehy 2.800 %	1,010,605	2.800 %	325 415 $
Daniel Yerace 2.800 %	1,010,605	2.800 %	325 415 $
Creative Planning LLC 1.787 %	645,104	1.787 %	207 723 $
Chris Calise 1.396 %	503,698	1.396 %	162 191 $
Meteora Capital LLC 1.236 %	446,251	1.236 %	143 693 $
Geode Capital Management LLC 0.5269 %	190,154	0.5269 %	61 230 $

Name	Equities	%	Valuation
Meteora Capital LLC -	1,197,074	-	26 336 $
RiverNorth Capital Management LLC -	150,000	-	3 300 $
Walleye Capital LLC -	109,050	-	2 399 $
Cantor Fitzgerald & Co. -	106,459	-	2 342 $
HRT Financial LLC -	100,115	-	2 203 $
Ionic Capital Management LLC -	93,559	-	2 058 $
Walleye Trading LLC -	72,560	-	1 596 $
SkyView Investment Advisors LLC -	55,122	-	1 213 $
Cowen & Co. LLC -	45,500	-	1 001 $
CSS LLC -	38,848	-	855 $

Coeptis Therapeutics Holdings, Inc.

105 Bradford Road Suite 420

15090, Wexford

http://www.coeptistx.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.32%	72TCr
NOVO NORDISK A/S	+34.28%	59TCr
JOHNSON & JOHNSON	-4.34%	37TCr
MERCK & CO., INC.	+20.27%	33TCr
ABBVIE INC.	+2.38%	28TCr
ASTRAZENECA PLC	+17.02%	24TCr
NOVARTIS AG	+9.31%	21TCr
ROCHE HOLDING AG	-5.07%	21TCr
PFIZER, INC.	+0.05%	17TCr